Matthias Alder
Known title: Chief Executive OfficerCIK: 0001370820
Associated companies
Transaction History
| GANX | ▲ Buy | Option Exercise | 18,750 | — | 3/26/2024 | View on chart |
| GANX | ▲ Buy | Option Exercise | 825 | — | 3/26/2024 | View on chart |
| GANX | ▲ Buy | Option Exercise | 637 | — | 3/26/2024 | View on chart |
| GANX | ▼ Sell | Tax Withholding | 6,085 | $25K | 3/26/2024 | View on chart |
| GANX | ▼ Sell | Open Market | 206 | $507 | 12/21/2023 | View on chart |
| GANX | ▲ Buy | Option Exercise | 637 | — | 12/20/2023 | View on chart |
| GANX | ▼ Sell | Open Market | 1,820 | $5K | 12/7/2023 | View on chart |
| GANX | ▲ Buy | Option Exercise | 825 | — | 10/1/2023 | View on chart |
| GANX | ▲ Buy | Option Exercise | 2,550 | — | 9/20/2023 | View on chart |
| GANX | ▲ Buy | Option Exercise | 3,300 | — | 7/1/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Gain Therapeutics Appoints CEO Gene Mack As Interim CFO
Gain Therapeutics has named CEO Gene Mack as the interim Chief Financial Officer, effective October 1. He is succeeding Gianluca Fuggetta in the role. This leadership change occurs while the stock trades significantly below the average analyst target price.
Gain Therapeutics Appoints CEO Gene Mack As Interim CFO. Gain Therapeutics has named CEO Gene Mack as the interim Chief Financial Officer, effective October 1. He is succeeding Gianluca Fuggetta in the role. This leadership change occurs while the stock trades significantly below the average analyst target price.